

APPLICANT(S): Steiner et al.  
SERIAL NO.: 09/449,817  
FILED: November 29, 1999  
Page 14

#### **REMARKS**

Claims 1, 7, 10-27, 54-57, 59 and 60 are pending in the application. Claims 1, 7, 10-27, 54-57, 59 and 60 have been rejected. Claims 1, 7, 12, 13, 14, 15, 16, 21, 24, 54, 55, 56 and 59 have been amended. New claims 61, 62 and 63 have been added. The amendments to the claims, specification and abstract and the incorporation of new claims are editorial in nature and contain no new matter. Therefore, Applicants respectfully request entry of the Amendment.

#### **PRIORITY**

In the Office Action, the Examiner objected to the granting of the benefit of priority to the Subject Application from United States non-Provisional Application No. 09/302,457, filed on April 29, 1999. The Examiner asserted that the elected subject matter, namely the identification of a human homologue of the p-Hyde gene and its product, allegedly has priority dating back to the filing date of the instant application, alone. Applicants respectfully disagree. In United States non-Provisional Application No. 09/302,457, Applicants clearly demonstrate the identification of a human p-Hyde gene homologue (figures 8, 9 and 19A). Thus Applicants request that the Examiner withdraw his objection.

#### **DRAWINGS**

In the Office Action, the Examiner noted that the drawings are considered informal. In response, Applicants hereby submit an amended set of formal drawings, in compliance with PTO form 948 attached to Paper No. 27. Accordingly, Applicants request withdrawal of the rejection.

#### **COMPLIANCE WITH THE SEQUENCE RULES**

In the Office Action, the Examiner noted that statement that the content of the paper and CRF copies include no new matter as required by 37 C.F.R. 1.821 through 1.825 in

APPLICANT(S): Steiner et al.  
SERIAL NO.: 09/449,817  
FILED: November 29, 1999  
Page 15

insufficient since it notes that the sequence listing is "forwarded herewith" and does not refer to the sequence listing filed April 16, 2001. In response, Applicants hereby submit an amended statement which refers to the sequence listing filed April 16, 2001. Accordingly, Applicants request withdrawal of the rejection.

### **OBJECTIONS TO THE SPECIFICATION**

In the Office Action, the Examiner objected to the specification as allegedly containing confusing reference materials. Specifically the Examiner asserted that "[t]roughout the application, for example on page 25, line 25, bracketed reference such as "[74]" are found but do not correlate to the reference citations at the end of the application....also, "?" are found throughout the specification".

In response, Applicants have corrected the specification to deleted the "?" and to delete the reference numbers in brackets and deleted the confusing references list at the end of the specification on pages 96-101. Accordingly, Applicants respectively request that the Examiner withdraw the objection.

### **CLAIM REJECTIONS - 35 U.S.C. § 112 SECOND PARAGRAPH**

In the Office Action, the Examiner asserted that claims 1, 7, 10-27, 54-57, and 59-60 are rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, by referring to the term "analogs".

In response, Applicants have amended claims 1, 7, 10-27, 54-57, and 59-60, removing all reference to the term "analog". It is respectfully asserted that the foregoing amendment merely addresses matters of form and does not change the literal scope of the claim in any way or result in any prosecution history estoppel. Therefore Applicants respectfully request Examiner withdraws the rejection.

APPLICANT(S): Steins et al.  
SERIAL NO.: 09/449,817  
FILED: November 29, 1999  
Page 16

In the Office Action, the Examiner rejected claim 16 under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, by referring to the term "sequence complementary to". In response, Applicants have herein amended claim 16 to refer to an isolated nucleic acid molecule having a nucleic acid sequence that is complementary to the nucleic acid sequence set forth in SEQ ID No. 1.

Both Claims 1 and 16 refer to a nucleic acid molecule. The Examiner objected to the nucleic acid molecule of claim 1 as allegedly encompassing DNA, which is double stranded and already contains a "complementary" sequence to the gene that encodes the protein. Applicants respectfully point out that as described in the specification on page 15 (lines 13-16), Applicants define a **nucleic acid** as comprising an **RNA or DNA** molecule in **either single or double stranded form**. Applicants claims to a complementary sequence, therefore recites **complementary RNA or DNA** which may be a single stranded DNA or RNA molecule with a nucleotide sequence that is complementary to the sequence as set forth in SEQ ID NO: 1. Therefore Applicants respectfully request that the Examiner reconsider and withdraw the rejection.

In the Office Action, the Examiner rejected claims 21-24 under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, by referring to the abbreviations "BAC".

In response, claim 21 has been amended. It is respectfully asserted that the foregoing amendment merely addresses matters of form and does not change the literal scope of the claim in any way or result in any prosecution history estoppel. Thus Applicants respectfully request that the Examiner reconsider and withdraw the rejection.

**CLAIM REJECTIONS - 35 U.S.C. § 112 FIRST PARAGRAPH**

APPLICANT(S): Stein et al.  
SERIAL NO.: 09/449,817  
FILED: November 29, 1999  
Page 17

In the Office Action, the Examiner rejected claims 1, 7, 10-27, 54-56 and 59 under 35 U.S.C. § 112, first paragraph as allegedly failing to clearly define a structural limitation of the claimed nucleic acid sequences. In response, Applicants have hereby amended claims 1, 7, 10-27, 54-56 and 59 to refer to an isolated nucleic acid molecule, comprising a nucleic acid sequence encoding a mammalian p-Hyde protein, with a nucleic acid sequence as set forth in SEQ ID No. 1. Applicants submit that the amended claims are thus definite, and respectfully request that the Examiner withdraw the rejection.

#### **CLAIM REJECTIONS - 35 U.S.C. § 101**

In the Office Action, the Examiner rejected claims 1, 7, 10-27, 54-57 and 59-60 under 35 U.S.C. § 101 as allegedly lacking patentable utility. Applicants respectfully traverse the Examiner's rejection. Applicants submit that the subject matter defined by the claims, namely the isolated nucleic acid molecule set forth in SEQ ID No. 1 is functionally characterized in the subject Application. Applicants have presented evidence in the Subject Application demonstrating an ability of a protein encoded by homologues/sequences of the Subject Application to induce cell-death-susceptibility in prostate cancer cells. Although the Examiner asserted that the rat p-Hyde protein has credible utility, the Examiner stated that: "The utility of the rat protein and gene cannot be translated into utility for the human protein and gene because it is unclear that the sequences are related".

Applicants respectfully disagree. Applicants submit that differential p-Hyde expression was evident in both rat and human prostate cancer cells, and that the sequences are highly homologous. If the gene product functions were unrelated, there would be no expectation for a comparable pattern of differential gene expression. Applicants therefore submit that comparable function and thereby utility has been demonstrated in the subject Application. Therefore, the claimed isolated nucleic acid molecule has a credible patentable utility. Accordingly, Applicants respectfully request that the rejection of claims 1, 7, 10-27, 54-57 and 59-60 under 35 U.S.C. § 101 be withdrawn.

#### **Claims Objections**

The Examiner asserted that Claim 7 is objected to for having an improper Markush group. According to the Examiner the members of a Markush group must be independent and non-overlapping. In Claim 7, the group "c-DNA" is included in the group "DNA"; thus, the Markush group is improper.

In response Applicants have amended Claim 7. Thus, claim 7 no longer contains an improper Markush group, and accordingly, Applicants respectfully request withdrawal of the rejection.

The Examiner objected to Claims 12-17 under 37 C.F.R. § 1.75 (c), as being allegedly of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim (s), or amend the claims (s) to place the claims(s) in proper depended form, or rewrite the claim(s) in independent form. According to the Examiner Claims 12-17 are drawn to complementary or antisense sequences, none of which are encompassed by Claim 1, as amended.

In response Applicants have amended Claims 12-16 and cancelled claim 17. Claim 12 is an independent claim, referring to an oligonucleotide specifically hybridizing with a nucleic acid molecule encoding a mammalian p-Hyde protein, wherein the nucleic acid molecule has a sequence as set forth in SEQ ID No: 1, with claims 13-15 dependent therefrom, and claim 16 is an independent claim, referring to an isolated nucleic acid molecule having a nucleic acid sequence complementary to the sequence as set forth in SEQ ID No: 1. It is respectfully asserted that the foregoing amendment merely addresses matters of form and does not change the literal scope of the claims in any way or result in any prosecution history estoppel. Thus, Applicants have rewritten the claims in proper independent form, and accordingly, Applicants respectfully request withdrawal of the rejection.

The Examiner asserted that Claim 14 is objected to for having allegedly an improper format and for being inconsistent with previous claims. A period is required at the end of the

claim. Also, the claim should depend from Claim 14 and cite—wherein the detectable marker—and not “wherein the oligonucleotide” for consistency with previous claims.

In response Applicants have amended Claim 14. Thus amended Claim 14 has a proper format, and is now consistent with previous claims. Accordingly, Applicants respectfully request withdrawal of the rejection.

The Examiner asserted that Claim 59 is objected to for allegedly depending from a non-elected claim, Claim 53.

In response Applicants have amended Claim 59 to depend from claim 7. Thus Claim 59 properly depends from an elected claim. Accordingly, Applicants respectfully request withdrawal of the rejection.

#### **REJECTIONS ON 35 U.S.C. § 102**

In the Office Action, the Examiner rejected claims 1, 7, 12, 13, 16 and 17 under 35 U.S.C. § 102(b), as allegedly being anticipated by Hillier et al. In response, Applicants respectfully traverse this rejection in view of the remarks that follow.

Claim 1 has been herein amended to recite an isolated nucleic acid molecule encoding for a mammalian p-Hyde protein having a nucleic acid sequence as set forth in SEQ ID No. 1. The Examiner has asserted that Hillier et al. disclose “a human mRNA EST sequence that matches 155 nucleotides of Applicants' SEQ ID No: 1”, yet does not comprise the sequence in its entirety, and therefore Hillier et al., does not anticipate claim 1.

The nucleotide sequence disclosed by Hillier et al., is not a p-Hyde coding sequence as set forth in SEQ ID No. 1. In order for Hillier et al to be anticipatory of claim 12, the Hillier nucleotide sequence must disclose the p-Hyde coding sequence. Hillier et al., do not disclose oligonucleotides per se, and do not disclose a sequence encoding p-Hyde, as the

sequence disclosed by Hillier et al does not in fact code for a functional protein. Thus Applicants submit that Hillier et al., does not anticipate claims 1 or 12.

Claim 16 has been amended to recite an isolated nucleic acid molecule comprising a nucleic acid sequence complementary to that set forth in SEQ ID No. 1. As in claim 1, Hillier et al do not disclose the full p-Hyde coding sequence, and hence does not anticipate claim 16.

Claim 17 has been cancelled.

Applicants respectfully assert that amended independent claims 1, and dependent claim 7, 12 and dependent claim 13, and 16, are allowable. Accordingly, Applicants respectfully request that the Examiner withdraw the rejections to claims 1, 7, 12, 13 and 16.

Further, in the Office Action, the Examiner rejected claims 1, 7, 10-21, 25-27, 54-56 and 59 under 35 U.S.C. § 102(b), as being anticipated by Talerman et al. In response, Applicants respectfully traverse this rejection in view of the remarks that follow.

The Examiner asserted that Talerman et al. disclose "a DNA sequence that is 72% similar and 39% identical to Applicants' SEQ ID No: 1". Claim 1 has been herein amended to recite an isolated nucleic acid molecule encoding for a mammalian p-Hyde protein having a nucleic acid sequence as set forth in SEQ ID No. 1. The Examiner has asserted that Talerman et al. does not comprise the complete sequence as set forth in SEQ ID No. 1. The nucleotide sequence disclosed by Talerman et al., does not encode for p-Hyde, and, moreover, is not functionally comparable. Talerman et al discloses TSAP sequences, which are known to function in upregulation of apoptosis in a p53-dependent manner, following p53 induction. In the instant invention, however, p-Hyde functions through a different mechanism, acting as both a tumor suppressor, and as an apoptotic inducer, via its ability to impair DNA repair enzyme function. Talerman et al do not disclose a molecule that functions to impair DNA repair enzyme function. Thus functionally, and structurally, TSAP as disclosed by Talerman et al., differs from the instant invention, and therefore does not anticipate Claim 1, or dependent claims thereof. Claims 7, 10, 11, 18-21, 25-27 and 59

directly depend from claim 1, and therefore Applicants maintain is not anticipated by Tallerman et al., accordingly.

Claim 12 has been amended to recite an oligonucleotide of at least 15 bases capable of specifically hybridizing with a nucleic acid molecule encoding a mammalian p-Hyde protein having a sequence as set forth in SEQ ID No. 1. In order for Talerman et al to be anticipatory of claim 12, the nucleotide sequence disclosed by Talerman et al. must teach the nucleotide sequences from which an oligonucleotide specifically hybridizing with a nucleic acid sequence encoding for p-Hyde protein are designed. Talerman et al., do not teach a sequence encoding p-Hyde, thus Applicants submit that Talerman et al., does not anticipate claim 12. Claims 13-15 directly depend from claim 12, and therefore Applicants maintain is not anticipated by Talerman, et al., accordingly.

Claim 16 has been amended to recite an isolated nucleic acid molecule comprising a nucleic acid sequence complementary to that set forth in SEQ ID No. 1. As in claim 1, Talerman et al., do not disclose a sequence encoding p-Hyde, and hence do not anticipate claim 16. Accordingly, Applicants respectfully assert that amended independent claim 16 is allowable.

The Examiner has stated that Tallerman et al. anticipates claims 54-56. Claims 54-56 recite a nucleic acid molecule of claim 1, with the further restriction that the nucleic acid sequence share at least 75 %, at least 85% or at least 95% identity with p-Hyde. The Examiner has in fact indicated that the greatest degree of identity is 39%, and only a 72% similarity. Similarity implies functional comparability, which Applicants submit is absent in Tallerman et al., further, Applicants least degree of identity claimed is 75 %, well above the values for both sequence identity and similarity, as claimed by Tallerman et al.



APPLICANT(S): Stein et al.  
SERIAL NO.: 09/449,817  
FILED: November 29, 1999  
Page 22


Therefore, Applicants respectfully assert that claims 1, 7, 10-21, 25-27, 54-56 and 59 are allowable. Accordingly, Applicants respectfully request that the Examiner withdraw the objections to the claims.

In view of the foregoing amendments and remarks, the pending claims are deemed to be allowable. Their favorable reconsideration and allowance is respectfully requested.

Should the Examiner have any question or comment as to the form, content or entry of this Amendment, the Examiner is requested to contact the undersigned at the telephone number below. Similarly, if there are any further issues yet to be resolved to advance the prosecution of this application to issue, the Examiner is requested to telephone the undersigned counsel.

Please charge any fees associated with this paper to deposit account No. 05-0649.

Respectfully submitted,



Mark S. Cohen  
Attorney for Applicant(s)  
Registration No. 42,425

Dated: July 28, 2003

**Eitan, Pearl, Latzer & Cohen Zedek, LLP**  
10 Rockefeller Plaza, Suite 1001  
New York, NY 10020  
Telephone: (212) 632-3494  
Fax: (212) 632-3489